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Association between bisphosphonate therapy and outcomes from 27 
rehabilitation in older people 28 
 29 
Abstract 30 
Background 31 
Bisphosphonate therapy may have actions beyond bone, including effects on cardiovascular, 32 
immune and muscle function. We tested whether bisphosphonate treatment is associated with 33 
improved outcomes in older people undergoing inpatient rehabilitation 34 
 35 
Methods 36 
Analysis of prospectively collected, linked routine clinical datasets. Participants were divided 37 
into never users of bisphosphonates, use prior to rehabilitation only, use after rehabilitation 38 
only, and current users (use before and after rehabilitation). We calculated change in 20-point 39 
Barthel scores during rehabilitation, adjusting for comorbid disease and laboratory data using 40 
multivariable regression analysis. Cox regression analyses were performed to analyse the 41 
association between bisphosphonate use and time to death or hospitalisation. 42 
 43 
Results 44 
2797 patients were included in the analysis. Current bisphosphonate users showed greater 45 
improvement in Barthel score during rehabilitation than non-users (5.0 points [95%CI 4.3 to 46 
5.7] vs 3.8 [95%CI 3.6 to 3.9]), but no difference compared to those receiving 47 
bisphosphonates only after discharge (5.1 [95%CI 4.6 to 5.5]). Previous bisphosphonate use 48 
was significantly associated with time to death (adjusted hazard ratio 1.41 [95%CI 1.15 to 49 
1.73]) but less strongly with time to combined endpoint of hospitalisation or death (adjusted 50 
hazard ratio 1.18 [95%CI 0.98 to 1.48]). Use after discharge from rehabilitation was 51 
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associated with reduced risk of death (adjusted hazard ratio 0.64 [95%CI 0.55 to 0.73]; 52 
hazard ratio per year of bisphosphonate prescription 0.98 [95%CI 0.97 to 0.99]) 53 
 54 
Conclusion 55 
Bisphosphonate use is unlikely to be causally associated with improved physical function in 56 
older people, but continuing use may be associated with lower risk of death. 57 
 58 
Keywords: Older, Bisphosphonate, rehabilitation, resilience 59 
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 61 
Introduction 62 
 63 
Bisphosphonates are widely used as antiresorptive agents for treating osteoporosis. They bind 64 
to bone with high affinity, impairing the ability of osteoclasts to adhere to and resorb bone; 65 
they also promote apoptosis of osteoclasts, impair maturation of osteoclast progenitors, and 66 
hence reduce bone turnover and resorption. The consequent increase in bone mineral density 67 
reduces the relative risk of post-menopausal osteoporotic fractures by between 30 and 70%1. 68 
In addition, bisphosphonate therapy may have effects beyond reducing fracture rates; in a 69 
recent meta-analysis, bisphosphonate therapy reduced all-cause mortality by 10% in high-risk 70 
groups, an effect that appears much greater than can be attributed solely to their effect on 71 
fracture reduction2,3. Furthermore, the reduction in all-cause mortality is not driven by 72 
reductions in specific major event groups (e.g. cardiovascular events, cancer or infection) but 73 
appears to be distributed across multiple causes of death4.    74 
 75 
Bisphosphonates have been shown to display a number of pleiotropic biological effects that 76 
might contribute to the above findings. First, nitrogen-containing bisphosphonates may 77 
exhibit actions on lipid metabolism similar to statin medications, via inhibition of the 78 
mevalonate pathway, thereby reducing the progression of atherogenic processes5-8. Statins 79 
themselves have been associated with improved outcomes from rehabilitation9,10. Related 80 
effects on the mevalonate pathway underlie alterations to lipid anchoring of a number of 81 
intracellular signalling molecules, which may explain the anticancer effects of 82 
bisphosphonates therapy observed in some studies. Effects on reducing oxidative stress have 83 
also been postulated; oxidative stress in turn has been linked to a wide range of disease states 84 
including cardiovascular disease11, cancer, and sarcopenia - the age-related loss of muscle 85 
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mass and strength12,13. Bisphosphonates may also initially promote low-grade, chronic 86 
inflammation (via production of pro-inflammatory cytokines14,15) which in turn may activate 87 
protective mechanisms at a cellular level which protect against the consequences of more 88 
severe inflammation.  Finally, recent preclinical data suggests that zoledronate can protect 89 
mesenchymal stem cells against the accumulation of DNA damage16. 90 
 91 
Rehabilitation is an essential step on the pathway back to independent function for older 92 
people who have suffered intercurrent illness. Whilst it is recognised that rehabilitation is 93 
dependent on a number of factors, not least the quality and input of an exercise programme, it 94 
can be interrupted by further intercurrent illness with a consequent vicious cycle of 95 
immobility, worsening physical function and increased susceptibility to illness. Rehabilitation 96 
may also progress slowly due to intrinsic pathophysiological limitations like sarcopenia. 97 
Successful rehabilitation in older people might thus be enhanced by agents with pleiotropic 98 
effects on a variety of biological pathways to improve resilience; agents that improve muscle 99 
function directly would clearly be useful, but agents that either reduce intercurrent illness or 100 
mitigate the effects of intercurrent illness may also be of benefit. We therefore tested whether 101 
bisphosphonate treatment was associated with improved outcomes in a large cohort of older 102 
people undergoing inpatient rehabilitation, using routinely collected health and functional 103 
data.  104 
 105 
Methods 106 
Data Sources and Patient Population 107 
This study was performed as part of a data linkage project which combined detailed 108 
healthcare data held on residents of Tayside, Scotland, held by the University of Dundee 109 
Health Informatics Centre (HIC) with functional outcome data on older people who had 110 
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undergone inpatient rehabilitation within the Dundee Medicine for the Elderly service 111 
(DOME). Data linkage was achieved using the Community Health Index (CHI), a unique 112 
healthcare identifier assigned to all Scottish healthcare users. Data linkage was carried out by 113 
HIC, with the combined, anonymised dataset hosted in a safe haven facility, which allows 114 
analysis by permitted parties without release of raw data outside the safe haven facility. 115 
 116 
The DOME functional outcome data forming the basis of this analysis has been described 117 
previously17,18. We used an extended version of this dataset, which was collected 118 
prospectively on all patients admitted for rehabilitation over a 13 year period between 1st 119 
January 1999 and 31st December 2011, and comprised approximately 5500 admissions on 120 
4382 individuals. The HIC database is a comprehensive set of health data on 400,000 people 121 
within the Tayside, Scotland area. In this study, health data was extracted from the HIC 122 
database for those patients registered on the DOME database. Prescribing information, 123 
biochemistry and haematology results, hospitalization data and diagnoses (Scottish Morbidity 124 
Register 01) coded using ICD-10 codes were available. Data on date of death was obtained 125 
via the Scottish Government Records Office, which records all deaths registered in Scotland. 126 
For this analysis, the cohort consisted of patients undergoing their first admission to the 127 
rehabilitation service, and omitted repeat admissions to the rehabilitation service, so that 128 
effects of previous rehabilitation did not impact on either baseline function or response to 129 
rehabilitation. 130 
  131 
Bisphosphonate use 132 
Bisphosphonate use was defined by extracting prescription records for bisphosphonate 133 
medications contained in the British National Formulary. All bisphosphonates used in the 134 
study population were included, namely alendronate, risedronate, etidronate, clodronate and 135 
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ibandronate. Zoledronic acid was not used within the service covered by this cohort during 136 
the time period under study. Data on prescribing are held only for prescriptions dispensed in 137 
the community, not in hospital; no electronic record exists for in-hospital prescriptions. We 138 
thus used community prescribing data from before and after each inpatient rehabilitation 139 
period to categorise patients into four groups: Current users comprised patients who were 140 
prescribed bisphosphonates at any time during the six months immediately prior and at any 141 
time in the 6 months subsequent to rehabilitation. Previous users comprised patients 142 
prescribed bisphosphonates in the two year period prior to rehabilitation, excluding those in 143 
group A. Subsequent users comprised patients who received bisphosphonates only after 144 
discharge from rehabilitation, and did not receive bisphosphonates in the two years prior to 145 
admission. Never users consisted of patients with no prescription for bisphosphonates 146 
recorded either before or after the rehabilitation stay at any point covered by the database 147 
(dating back to 01/01/1998 and censored at 04/05/2012). This approach allowed us to dissect 148 
out whether changes associated with bisphosphonate use were likely to be due to 149 
bisphosphonates, or due to unmeasured characteristics of patients who were more likely to be 150 
prescribed bisphosphonates. Relatively wide time windows were employed in part due to the 151 
known long duration of action of bisphosphonate medications, and because prescriptions for 152 
bisphosphonates are renewed infrequently due to the weekly dosing of many preparations.  153 
 154 
 155 
Measurement of functional status 156 
The functional outcome utilised in this study was the 20 point Barthel Index19, a widely used 157 
and validated measure of patients’ abilities in activities of daily living. The Barthel index 158 
consists of 10 separate function categories each with possible scores of 0/1, 0/1/2, or 0/1/2/3, 159 
yielding a total score out of 20, with a higher score indicating greater independence. A 160 
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Barthel score was recorded by rehabilitation staff at admission and at discharge from 161 
inpatient rehabilitation. Discharge destination (coded as return to own home or elsewhere) 162 
was obtained from the rehabilitation dataset. 163 
 164 
Comorbidities and other covariates 165 
Covariates were selected on the basis of clinical plausibility and prior knowledge, based on 166 
their likelihood to interact with bisphosphonate therapy, affect rehabilitation outcome, 167 
physical function or susceptibility to illness. Age and sex were obtained from healthcare 168 
demographic information held within HIC data. Previous hospitalisation for myocardial 169 
infarction, stroke, COPD and heart failure were coded from ICD-10 codes held in HIC 170 
healthcare data. Previous diagnoses of cancer were obtained from SMR06 (Scottish Cancer 171 
Registry) data, and previous diagnoses of diabetes mellitus were obtained from the Scottish 172 
Care Information - Diabetes Collaboration (SCI-DC) database, which records all diagnoses of 173 
diabetes within Scotland. Renal function (recorded as estimated glomerular filtration rate 174 
[eGFR] and calculated by the Modified Diet in Renal Disease [MRDR4] equation20, serum 175 
calcium and serum albumin values were extracted from routinely collected biochemistry data 176 
held in HIC; the value closest to the date of admission to rehabilitation was used. Prescribed 177 
calcium and vitamin D supplementation was assessed by extraction of prescribing data in a 178 
similar way to bisphosphonate medication. 179 
 180 
Data Analysis 181 
Data analyses were performed using SPSS v21 (IBM, New York, USA) or SAS v9.2 (SAS 182 
Institute Inc., Cary, NC, USA). Patients who died during admission or had a missing 183 
admission or discharge Barthel score were excluded from analysis. Where patients had had 184 
multiple admissions to the rehabilitation service, only the first admission was included in the 185 
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analysis, and subsequent admissions were ignored. Baseline factors were compared by 186 
bisphosphonate use, using one-way ANOVA for normally distributed continuous variables, 187 
Kruskal-Wallis test for non-normally distributed continuous variables, and Pearson’s Chi-188 
squared test for categorical variables. The association between bisphosphonate use and 189 
improvement in Barthel score during rehabilitation was assessed by multivariable regression 190 
analysis, adjusting for age, sex, admission Barthel score, calcium/vitamin D use, renal 191 
function (eGFR), albumin, corrected calcium, previous diagnosis of diabetes mellitus, 192 
previous indication of IHD, stroke, cancer, COPD and CHF, and number of prescribed 193 
medications. A sensitivity analysis was conducted excluding those patients who had received 194 
non-aminobisphosphonates (clodronate or etidronate) due to their lack of effect on the 195 
mevalonate pathway. Because calcium and vitamin D are almost always co-administered with 196 
bisphosphonates, we analysed whether calcium and vitamin D use was associated with 197 
differences in rehabilitation outcomes, death or time to hospitalisation in the group of patients 198 
who had never taken bisphosphonates; if a significant effect were to be evident, the results of 199 
analyses of bisphosphonate exposure would not be reliably attributable to bisphosphonates. 200 
For those taking bisphosphonates prior to rehabilitation, the number of days of exposure in 201 
the year prior to rehabilitation was calculated – those on weekly preparations counted as 7 202 
days per exposure, those on monthly preparations counted as 30 days per exposure. 203 
Adherence, which is known to be suboptimal with oral bisphosphonates, could not be directly 204 
calculated as data on encashed prescriptions was available, but date of decision to commence 205 
prescribing was not. 206 
 207 
We conducted Cox regression analyses to estimate the association between bisphosphonate 208 
use and time to death after discharge from rehabilitation; similar analyses were conducted for 209 
time to a combined endpoint of death or next hospitalisation. For each analysis, models were 210 
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run both unadjusted and adjusted for the variables listed above including discharge 211 
destination. Models were run comparing each of the groups against those patients never using 212 
bisphosphonates. To separate out the effect of previous exposure to bisphosphonates (which 213 
might be a marker for unmeasured frailty or comorbidity) from the effect of subsequent use, a 214 
separate analysis was run using any use prior to rehabilitation as a distinct variable from any 215 
use after discharge from rehabilitation. Further analyses were run using time-dependent Cox 216 
regression analyses; the cumulative exposure to bisphosphonates post-discharge was included 217 
as a time-dependent variable, with pre-admission exposure included as a categorical variable 218 
and other adjusting variables included as listed above. 219 
  220 
11 
 
 221 
Results 222 
Data were available on 4382 first admissions to rehabilitation. 95 patients were omitted from 223 
the analysis because they had last received bisphosphonates greater than 2 years prior to 224 
admission. 366 patients died during their rehabilitation stay (27/392 [6.9%] of previous 225 
bisphosphonate users versus 339/3895 (8.7%) of never users, p=0.22). Of the remainder of 226 
the cohort, 1124 patients were excluded due to missing admission or discharge Barthel data. 227 
Analyses were therefore conducted on the remaining 2797 patients. Table 1 gives the baseline 228 
details for the four analysis groups.  229 
 230 
No effect of calcium and vitamin D supplementation was evident on either rehabilitation 231 
outcomes (3.8 points vs 3.7 points improvement during rehabilitation, p=0.15), risk of death 232 
(hazard ratio 0.90, 95%CI 0.72 to 1.12), or risk of hospitalisation or death (hazard ratio 0.99, 233 
95%CI 0.81 to 1.21) in the group of patients who had never used bisphosphonates. Calcium 234 
and vitamin D use was included as a covariate in all subsequent analyses. Table 2 shows the 235 
association between different patterns of bisphosphonate exposure and improvements seen in 236 
Barthel score during inpatient rehabilitation, giving both unadjusted results and results 237 
adjusted for the variables listed above. Excluding those patients who had used non-nitrogen-238 
containing bisphosphonates (clodronate or etidronate) did not significantly change the results 239 
(adjusted improvement in Barthel scores for never, previous, current and subsequent users: 240 
3.8 [3.6 to 3.9]; 3.7 [2.9 to 4.5]; 5.8 [4.9 to 6.6]; 5.1 [4.6 to 5.5]; p=0.17 for current vs 241 
subsequent users). Exposure to bisphosphonates in the year prior to rehabilitation varied, with 242 
43% of those taking bisphosphonates prior to rehabilitation taking less than 180 days 243 
equivalent in the year prior to admission. However there was no significant correlation 244 
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between the number of days of bisphosphonate use in the year prior to rehabilitation and the 245 
improvement in Barthel score (unadjusted r=-0.05, p=0.49; adjusted r=-0.12, p=0.15)  246 
 247 
Table 3 gives the results of both unadjusted and adjusted Cox regression analyses, showing 248 
the effect of exposure to bisphosphonates post-discharge on both survival and time to the 249 
combined death or next hospitalisation endpoint. Time-dependent Cox regression analyses 250 
showed similar results; the adjusted hazard ratio for death post-discharge was 0.98 (95%CI 251 
0.97 to 0.99) per year of post-discharge bisphosphonate exposure, and the adjusted hazard 252 
ratio for death or next hospitalisation post-discharge was 1.01 (95%CI 0.98 to 1.04) per year 253 
of post-discharge bisphosphonate exposure.  254 
 255 
 256 
Discussion 257 
The results from this analysis do not support a beneficial effect of bisphosphonate use on 258 
physical function outcomes in rehabilitation, as measured by the Barthel score. Although 259 
current bisphosphonate users achieved greater improvement in function during rehabilitation 260 
compared to previous users and never users, current users showed similar improvements to 261 
those who used bisphosphonates only after discharge from rehabilitation. For this latter 262 
group, drug exposure occurred only after discharge from rehabilitation and thus their 263 
functional improvement cannot be attributed to the effects of bisphosphonates. Our results do 264 
not therefore support a causal association between bisphosphonate therapy and functional 265 
improvement in this cohort. For post-discharge time to death and to next hospitalisation, our 266 
results suggest that previous exposure to bisphosphonates is a marker of increased risk of 267 
death or hospitalisation, but that ongoing exposure to bisphosphonates is associated with 268 
reduced hazard of death, and a less significant reduction in hazard of hospitalisation. 269 
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 270 
To our knowledge, this is the first study to examine the relationship between bisphosphonate 271 
use and functional outcomes during rehabilitation. The results of our analyses do not suggest 272 
a biological effect of bisphosphonates on biological pathways that might improve 273 
performance during rehabilitation – either via direct effects on musculoskeletal function or by 274 
reducing adverse events that interrupt rehabilitation. Rather, the results are consistent with 275 
current and future bisphosphonate use being a marker for unmeasured patient characteristics 276 
that are associated with better rehabilitation outcomes. Fitter, more robust patients who are 277 
perceived as having more to gain and longer to live may be more likely to be given 278 
bisphosphonates, and although the Barthel scores at admission to rehabilitation were similar 279 
across all four groups, there are other aspects of physical function and frailty that we were 280 
unable to measure directly using this routinely collected dataset, including adherence to 281 
rehabilitation processes during the inpatient stay. 282 
 283 
A further potential confounder to address in this context is the frequent co-administration of 284 
calcium and vitamin D in routine treatment with bisphosphonates. UK clinical guidelines 285 
state that clinicians should ensure patients have an adequate intake of calcium and are vitamin 286 
D replete before prescribing bisphosphonates. The majority of older, frail patients in Scotland 287 
have low 25-hydroxyvitamin D levels – and patients in our cohort were even more likely to 288 
have low levels given their prolonged stay in hospital. In the absence of vitamin D repletion, 289 
the increases in bone mineral density and anti-fracture efficacy associated with 290 
bisphosphonates, are attenuated21. Vitamin D has a direct effect on muscle function22, and 291 
therefore supplementation with this agent could confound the association between 292 
bisphosphonates and functional outcomes. We did not have data on 25-hydroxyvitamin D 293 
levels for this cohort, and thus we cannot completely adjust for the effect that vitamin D 294 
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repletion might have had on the analyses. However, analysis of the large group of patients 295 
who had never received a bisphosphonate did not support an effect of calcium and vitamin D 296 
on rehabilitation outcomes, survival or hospitalisation in this group, making this explanation 297 
less likely. 298 
 299 
The results from analysis of time to death are broadly consistent with other randomised trial 300 
and observational data3,4,23,24 suggesting that bisphosphonates are associated with a lower risk 301 
of death. This is despite the fact that previous bisphosphonate use appears to be a risk marker 302 
for higher rates of death and hospitalisation. Such a finding, whilst paradoxical at first sight, 303 
is consistent with the fact that bisphosphonates will typically be used in those with a disease 304 
(osteoporosis) with major adverse consequences on fitness and function, which is itself 305 
associated with other life-shortening disease complexes (particularly cardiovascular 306 
disease5,25). Thus being prescribed bisphosphonates at some previous time may be a marker 307 
of a group at increased risk of death, but greater exposure to bisphosphonates themselves 308 
could still confer protective effects. Less striking results were seen on analysing time to 309 
hospitalisation or death; some previous studies have suggested lower death rates with 310 
bisphosphonate use, but not lower event rates for vascular disease. This would be consistent 311 
with our findings, and one possibility is that bisphosphonates might not reduce event rates, 312 
but might reduce the severity or impact of events on homeostatic function – i.e. they might 313 
enhance biological resilience26 via yet to be determined mechanisms. It is noteworthy that the 314 
more potent bisphosphonates are known to induce an acute-phase inflammatory response in 315 
some users2; inflammatory responses are also thought to contribute to the pathophysiology 316 
underlying phenomena such as ischaemic preconditioning in different organ systems27,28. 317 
Another possible mechanism is via anti-apoptotic effects; although bisphosphonates promote 318 
apoptosis of osteoclasts, they inhibit apoptosis of osteoblasts and osteoclasts, possibly via 319 
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effects on pathways linked to connexin 43 29,30. Similar pathways are present in other tissues, 320 
including cardiomyocytes31, although the actions of bisphosphonates on apoptosis in human 321 
organ systems outwith bone remain to be elucidated. 322 
 323 
Our study had a number of significant strengths. The dataset combined detailed health and 324 
functional outcomes data on a large set of patients undergoing rehabilitation in the real world, 325 
which enhances the generalisability of the data. Use of prescribing data from both before and 326 
after rehabilitation allowed us to test causal relationships in a way that would not have been 327 
possible without post-discharge prescribing data; these data enabled a more robust schema to 328 
be used to determine bisphosphonate treatment level (including use up to two years prior to 329 
rehabilitation and subsequent use), as opposed to a simple dichotomous indicator of treatment 330 
or no treatment at admission. Furthermore, the prescribing data comprises prescriptions 331 
encashed by patients and dispensed by pharmacists, rather than merely prescriptions written 332 
by physicians, thus the prescribing data may better reflect medication adherence than 333 
measures based on analysing numbers of prescriptions written. Combining detailed 334 
biochemical data allowed us to adjust analyses for albumin and renal function, both of which 335 
are important potential confounders.  336 
 337 
A number of weaknesses deserve comment. The use of routine data limits the type of 338 
measures of frailty and function to those available from clinical practice when the data were 339 
collected, and missing data are frequent. Adherence was not measured directly; although 340 
prescriptions were dispensed we have no measure of ingestion of medication. Furthermore, 341 
we cannot account for medications available without prescription, which included low-dose 342 
calcium and vitamin D. Although intravenous bisphosphonates such as ibandronate and 343 
zoledronate were not used within our service (which included osteoporosis management) 344 
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during the time period studied, we cannot exclude the possibility that a few patients received 345 
courses of intravenous bisphosphonates (e.g. to treat hypercalcaemia of malignancy) via 346 
oncology or other services; community prescribing data does not capture this use. We did not 347 
attempt to distinguish between different types of bisphosphonate; the majority of patients 348 
took once-weekly oral bisphosphonates. Although there may be different effects between 349 
different agents, the effects on mortality from trials appear to be broadly consistent in meta-350 
analysis3. A further potential limitation is that we did not have access to 25-hydroxyvitamin 351 
D or PTH levels on patients; we are therefore unable to test whether vitamin D insufficiency 352 
or secondary hyperparathyroidism might modify the results of our analysis.  353 
 354 
Bisphosphonates have a long duration of action on bone32, in part because they bind to 355 
hydroxyapatite crystals. The time course of biological effects in other organ systems is less 356 
clear33; our analysis assumes an extended duration of action after dosing, but this may not be 357 
the case for all potential biological effects. Similarly, the effects of bisphosphonates in this 358 
analysis are difficult to fully separate from any effects of calcium and vitamin D, both of 359 
which are known to have pleiotropic biological effects across multiple organ systems22. 360 
Finally, the cohort that we used comprised older patients selected for inpatient rehabilitation, 361 
and the cohort was exclusively white and mostly Northern European in ancestry. The findings 362 
from this cohort are not therefore necessarily generalizable to cohort comprising younger, 363 
fitter patients, unselected older patients or patients with different racial or ethnic background.  364 
 365 
Our work suggests a number of avenues for future research. Replication of these findings in 366 
other cohorts would be of interest to ensure that an effect has not been missed by our 367 
analysis. Although the lack of evidence for a causal relationship between bisphosphonate use 368 
and improved rehabilitation outcomes does not support conducting trials in this specific area, 369 
17 
 
the idea that bisphosphonates might be able to reduce death rates in older people by 370 
mitigating the deleterious impact of health events is an intriguing one, which merits further 371 
study. Studies designed specifically to examine this idea are needed, and should not be 372 
confined to patients with osteoporosis; both studies to explore possible biological 373 
mechanisms for the lower mortality seen in bisphosphonate users, and studies to test whether 374 
such an effect can be reproduced in those without osteoporosis, would be of considerable 375 
interest. 376 
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Table 1. Baseline Details (n=2797) 471 
 472 
 Never used Previous use Current use Subsequent use 
N (%) 2351 (84) 124 (4) 95 (3) 227 (8) 
Mean age (SD) 84.2 (7.6) 83.3 (6.9) 84.7 (6.3) 83.7 (7) 
Male sex (%) 1056 (45) 24 (19) 15 (16) 58 (26) 
Median length of stay (IQR) 36 (46) 33 (44) 35 (46) 38 (40) 
Previous myocardial infarction (%) 533 (23) 38 (31) 33 (35) 41 (18) 
Previous stroke (%) 533 (23) 17 (14) 17 (18) 41 (18) 
Previous heart failure (%) 370 (16) 22 (18) 14 (15) 14 (6) 
Previous hip fracture (%) 188 (8) 10 (8) 11 (12) 47 (21) 
Previous COPD (%) 299 (13) 33 (27) 20 (21) 27 (12) 
23 
 
Previous diagnosis of cancer (%) 290 (12) 18 (15) 7 (7) 25 (11) 
Diabetes mellitus (%) 418 (18) 20 (16) 11 (12) 37 (16) 
Mean admission Barthel score (SD) 10.4 (3.9) 10.9 (3.4) 10.5 (3) 10.9 (3.2) 
Median no of medications at admission (IQR) 2 (5) 3 (6) 7 (4) 2 (3) 
Discharged to own home (%) 1743 (74) 97 (78) 87 (92) 202 (89) 
Mean adjusted serum calcium (mmol/L) (SD) 2.4 (0.1) 2.4 (0.1) 2.4 (0.1) 2.4 (0.1) 
Mean eGFR (ml/min) (SD) 61.2 (23.7) 68 (31.5) 64.5 (28.2) 65.2 (23.2) 
Mean haemoglobin (g/dL) (SD) 12.1 (1.9) 11.7 (1.8) 11.9 (2.2) 11.8 (1.8) 
Mean albumin (g/L) (SD) 36.7 (4.9) 36.0 (4.6) 37.5 (4.5) 36.9 (4.9) 
 473 
  474 
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Table 2. Association between Bisphosphonate use and change in Barthel Score during Rehabilitation 475 
 476 
 Never used Previous use Current use Subsequent use 
Unadjusted change in Barthel score (95% CI) 3.8  
(3.6-3.9) 
3.4  
(2.8-4.0) 
5.2** 
(4.6-5.9) 
5.0**  
(4.6-5.5) 
Adjusted change in Barthel score (95% CI) 3.8  
(3.6-3.9) 
3.4  
(2.8-4.0) 
5.0 ** 
(4.3-5.7) 
5.1**  
(4.6-5.5) 
Unadjusted length of stay (95% CI) (days) 57  
(54.6-59) 
46 
(36-57) 
51  
(39-63) 
54 
(47-62) 
Adjusted length of stay (95% CI) (days) 56  
(54-58) 
50 
(40-59) 
62  
(50-73) 
54 
(47-61) 
 477 
*P<.05, **P<.001 vs never users 478 
Adjusted for: Baseline Barthel score, age, sex, comorbid disease (myocardial infarction, stroke, heart failure, chronic obstructive pulmonary disease, diabetes 479 
mellitus, previous cancer), medication burden, recent hip fracture, baseline albumin, calcium, renal function (eGFR), and haemoglobin 480 
Barthel score range 0 to 20; higher values indicate better function 481 
  482 
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Table 3. Cox Regression Analysis for Time to Death or next Hospitalisation 483 
 Never used 
(n=2459) 
Previous use 
(n=133) 
Current use 
(n=100) 
Subsequent use only 
(n=237) 
Unadjusted hazard ratio for death (95% CI) 1 1.39 (1.13 to 1.69) 0.79 (0.62 to 1.00) 0.50 (0.43 to 0.60) 
Adjusted hazard ratio for death (95% CI) 1 1.41 (1.15 to 1.73) 1.00 (0.77 to 1.29) 0.57 (0.48 to 0.67) 
Unadjusted hazard ratio for next 
hospitalisation or death (95% CI) 
1 1.21 (1.00 to 1.45) 1.20 (0.98 to 1.47) 0.81 (0.71 to 0.93) 
Adjusted hazard ratio for next 
hospitalisation or death (95% CI) 
1 1.18 (0.98 to 1.48) 1.27 (1.01 to 1.59) 0.88 (0.77 to 1.02) 
 Previous use vs no previous use Use post-discharge vs no use post-discharge 
Unadjusted hazard ratio for death (95% CI) 1.13 (0.97 to 1.32) 0.56 (0.48 vs 0.65) 
Adjusted hazard ratio for death (95% CI) 1.32 (1.11 to 1.56) 0.64 (0.55 to 0.73) 
Unadjusted hazard ratio for next 
hospitalisation or death (95% CI) 
1.23 (1.07 to 1.41) 0.89 (0.79 to 1.00) 
Adjusted hazard ratio for next 
hospitalisation or death (95% CI) 
1.24 (1.06 to 1.44) 0.95 (0.84 to 1.08) 
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